Introduction Clinical evidence suggests that first-line immune checkpoint inhibitor (ICI)
combination therapies can improve survival in patients with advanced non-squamous non …

Background: Recently, several clinical studies have evaluated the first-line use of immune
checkpoint inhibitors (ICIs) combined with platinum-doublet chemotherapy in patients with …

Background: Checkpoint inhibitors plus platinum-based chemotherapy have shown
superiority compared to chemotherapy alone as first-line therapy in advanced non–small …

Background Non‐small cell lung cancer (NSCLC) is the predominant type of lung cancer,
and most clinically curable patients are diagnosed with locally advanced disease. Although …

Introduction: The combination of immune checkpoint inhibitors (ICIs) and chemotherapy is a
promising first-line therapy for patients with advanced non-squamous non-small cell lung …

Introduction Recent clinical trials have confirmed that anti-programmed cell death-1/ligand 1
(anti-PD-1/L1) combined with either anti-cytotoxic T-lymphocyte-associated protein 4 (anti …

Purpose Combination therapies with immune checkpoint blockade demonstrate promising
antitumor activity and safety in Non-small Cell Lung Cancer (NSCLC). However, whether the …

Objective Currently, several immune checkpoint inhibitors (ICIs) treatment for advanced non‐
small‐cell lung cancer (NSCLC) have been investigated; their overall efficacy and safety …

Background Immune-checkpoint inhibitors (ICIs) combined with chemotherapy are emerging
as an effective first-line treatment in advanced non-small cell lung cancer (NSCLC); …

Abstract Backgrounds Immune checkpoint inhibitors (ICIs) alone or in combination with
chemotherapy (CT) are the standard of care for first-line therapy in metastatic non-small cell …